A Multicentre, Single Arm, Observational Phase IV Study to Assess the Safety and Efficacy of Nelarabine in Children and Young Adults (up to 21 Years of Age) With Relapsed or Refractory T-Lineage Acute Lymphoblastic Leukaemia or Lymphoblastic Lymphoma.

Trial Profile

A Multicentre, Single Arm, Observational Phase IV Study to Assess the Safety and Efficacy of Nelarabine in Children and Young Adults (up to 21 Years of Age) With Relapsed or Refractory T-Lineage Acute Lymphoblastic Leukaemia or Lymphoblastic Lymphoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2015

At a glance

  • Drugs Nelarabine (Primary)
  • Indications Acute lymphoblastic leukaemia; Lymphoma
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jul 2014 Planned End Date changed from 1 Apr 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 07 Jul 2014 Planned primary completion date changed from 1 Apr 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top